The mission of IMI2 is to “improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need”1. Therefore, the ultimate impact that IMI projects can have is to enable the development, approval and access to effective and affordable medicines. There is an implicit assumption that spending on research and development (R&D) through the activities of the IMI neurodegeneration project portfolio might improve innovation in this disease area. Therefore, if we want to assess the impact of the IMI neurodegeneration project portfolio, we will need to identify :
(1) what factors are likely to facilitate pharmaceutical innovation in neurodegenerative diseases, and
(2) how is the IMI neurodegeneration project portfolio contributing to these factors
D1.4 First report on impact of IMI neurodegeneration portfolio
